健康な成人参加者における経口投与ABBV-1042の体内動態と有害事象を評価する研究
第Ⅰ相二重盲検プラセボ対照初回ヒト試験:健常被験者におけるABBV-1042単回漸増投与の安全性、忍容性、および薬物動態の評価
This study will assess the adverse events, tolerability, and how oral ascending doses of ABBV-1042 moves through the body of healthy adult participants.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Illinois
-
Grayslake、Illinois、アメリカ、60030
- Acpru /Id# 279405
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
- Body weight ˃ 45 kg at the time of screening and upon initial confinement.
- A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG
Exclusion Criteria:
- History of suicidal ideation within one year prior to study treatment administration and/or history of suicidal behavior or non-suicidal self-injury within two years prior to study treatment administration as evidenced by any "yes" answer to questions on the Columbia-Suicide Severity Rating Scale (C-SSRS) at the screening visit or upon initial confinement.
- Current or past history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine (including diabetes mellitus, thyroid disorders), malignancy, hematological, immunological, neurological, or psychiatric disease that, , in the opinion of the investigator, could compromise either participant safety or the results of the trial.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:ABBV-1042 or Placebo-Group 1
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
|
実験的:ABBV-1042 or Placebo-Group 2
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
|
実験的:ABBV-1042 or Placebo-Group 3
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
|
実験的:ABBV-1042 or Placebo-Group 4
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
|
実験的:ABBV-1042 or Placebo-Group 5
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
|
実験的:ABBV-1042 or Placebo-Group 6
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants Experiencing Adverse Events
時間枠:Up to approximately 32 days
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to approximately 32 days
|
|
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements
時間枠:Up to approximately 3 days
|
Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed. |
Up to approximately 3 days
|
|
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
時間枠:Up to approximately 3 days
|
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior. |
Up to approximately 3 days
|
|
Number of Participants with Abnormal Change in Physical Examinations
時間枠:Up to approximately 3 days
|
Number of participants with abnormal change in physical examinations in areas like cardiovascular, respiratory, and neurological systems will be assessed. |
Up to approximately 3 days
|
|
Number of Participants with Change from Baseline in Electrocardiogram (ECG)
時間枠:Up to approximately 3 days
|
12-lead resting ECG will be recorded. |
Up to approximately 3 days
|
|
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
時間枠:Up to approximately 3 days
|
Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed. |
Up to approximately 3 days
|
|
Maximum Plasma Concentration (Cmax) of ABBV-1042
時間枠:Up to approximately 3 days
|
Cmax of ABBV-1042 |
Up to approximately 3 days
|
|
Time to Cmax (Tmax) of ABBV-1042
時間枠:Up to approximately 3 days
|
Tmax of ABBV-1042 |
Up to approximately 3 days
|
|
Apparent terminal phase elimination constant (β) of ABBV-1042
時間枠:Up to approximately 3 days
|
β of ABBV-1042 |
Up to approximately 3 days
|
|
Terminal Phase Elimination Half-Life (t1/2) of ABBV-1042
時間枠:Up to approximately 3 days
|
t1/2 of ABBV-1042 |
Up to approximately 3 days
|
|
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCt) of ABBV-1042
時間枠:Up to approximately 3 days
|
AUCt of ABBV-1042 |
Up to approximately 3 days
|
|
Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of ABBV-1042
時間枠:Up to approximately 3 days
|
AUCinf of ABBV-1042 |
Up to approximately 3 days
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:ABBVIE INC.、AbbVie
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。